FORMULATION ARTICLES

FORMULATION VIDEOS

As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today.

Unlike conventional predictive biomarkers, which often focus on isolated molecular markers, this strategy integrates spatial metabolomics and genomics, providing a multidimensional perspective.

Discover the unparalleled flexibility and automation that sets the IJM NanoScaler Pro apart from other lipid nanoparticle systems.

Explore constructing a modular RNA-LNP GMP facility using Cytiva's FlexFactory™ process train in a KUBio™ environment to scale RNA-LNP therapies.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS